Implantation of retrovirus-producing cells within a tumor has been demonstrated to eliminate malignant brain tumors effectively in animal models. In our previous study, the implantation of high-titer retrovirus-producing fibroblasts into tumors resulted in highly efficient transduction in vivo. The transduced glioma cells migrated far from the implantation site, potentiating the induction of the remarkable bystander effect. It is also possible, however, that the implantation of murine fibroblast-derived virus-producing cells may induce an immune response in patients. In this study, we prepared retroviruses carrying the herpes simplex virus thymidine kinase (HTK) gene with titers of 1.4-2.5 × 10 11 colony-forming units (c.f.u.)/ml, and stereotactically inoculated only 3 l of
Introduction
Glioblastoma multiforme constitutes the most common malignant form of gliomas and represents nearly 10% of all gliomas. 1 The growth of glioblastoma is usually restricted to the brain, but the rapid migration of glioblastoma cells into the normal brain parenchyma followed by their rapid growth produces a fatal increase of intracranial pressure in brain tumor patients. The natural course of glioblastoma results in a median life expectancy of approximately only 1 year, and the outcome remains very poor, despite treatment with current modalities such as surgery, radiotherapy and chemotherapy.
One potential therapeutic modality for glioblastoma is the use of suicide genes such as the herpes simplex virus thymidine kinase (HTK) gene. When tumor cells are transduced with the HTK gene and exposed to the antiviral drug ganciclovir (GCV), phosphorylated GCV, which is formed by HTK but not by mammalian enzymes, causes a block in DNA replication and conse-the HTK-bearing retroviruses into the brain tumors of mice. Following repetitive ganciclovir (GCV) intraperitoneal injection, effective killing of glioma cells in the mouse brain was observed. The transduction efficiency was nearly as high as that observed for the implantation of high-titer retrovirus-producing fibroblasts. Eighty percent of brain tumor-bearing mice were completely cured by our treatment protocol using concentrated HTK-harboring retroviruses. Our results suggest that repeated inoculations of high-titer retroviruses carrying the HTK gene followed by GCV treatment may be a promising strategy for the clinical treatment of malignant gliomas. Gene Therapy (2001) 8, 215-222. quent cell death. 2, 3 Other modalities of enzyme-prodrug systems have also been recently developed. They include Escherichia coli cytosine deaminase/5-fluorocytosine, human cytochrome p450 2B1/cyclophosphamide and Escherichia coli guanine-phosphoribosyltransferase/6-thioxantine. 4 These systems also appear to hold promise for therapeutic use.
The preferential integration of retroviruses into the genome of actively dividing cells makes them one of the most preferable vectors for cancer therapy. 5 However, the low efficiency of retrovirus-mediated gene transfer to tumor cells in vivo presents a major restriction for this therapeutic modality. Direct inoculation of retroviruses containing the lacZ gene (the Escherichia coli ␤-galactosidase gene) into experimental tumors resulted in transduction of approximately 0.1% of the tumor. On the other hand, gene transfer to tumor cells was significantly increased to 10 to 50% by the inoculation of retrovirusproducing cells into the tumor. 6, 7 The difference might be explained by a continuous release of retroviruses from producer cells allowing the transduction of the gene into proliferating cells for several days.
Recently, we have developed high-titer retrovirus-producing fibroblasts through the introduction of the polyoma early gene 8 and have demonstrated the transduction of the lacZ gene into a large number of glioma cells by the implantation of improved retrovirus-producing fibroblasts in the tumor. 9 Furthermore, these transduced glioma cells were capable of migrating and moving within the tumor. We also reported the rapid migration of genetically labeled murine RSV-M glioma cells following inoculation into normal murine brains and brain tumors. 10, 11 Our results have led us to propose three critical factors that determine therapeutic efficacy in the elimination of malignant glioma cells by the HTK/GCV system: first, the use of high-titer retrovirus-producing fibroblasts; second, the site into which the retrovirus-producing fibroblasts are implanted within the tumor; and third, the therapeutic schedule dictating the start of GCV treatment following the implantation of retrovirusproducing fibroblasts. 9, 11, 12 In view of the ultimate goal of eradicating malignant glioma cells in the human brain, we believe that the direct inoculation of retrovirus is more favorable than the implantation of murine retrovirus-producing fibroblasts in the brain, if the transduction efficiency around the inoculation site is comparable to that of retrovirus-producing fibroblasts. Kuriyama et al 12 have treated subcutaneously implanted hepatoma cells with retrovirus and demonstrated the effective elimination of the cancer. However, their experiments necessitated the use of 100 l of retroviral solution, and this volume of retrovirus cannot be injected into the mouse brain. In this study we prepared HTK-bearing retroviruses with titers as high as 1.4-2.5 × 10 11 c.f.u./ml by the use of our improved packaging cell line. 8 Direct inoculation of 3 l of retrovirus preparation bearing the HTK gene into the brain tumor followed by GCV-treatment effectively eliminated malignant glioma cells, potentiating the use of this method in clinical applications.
Results
Effective transduction by the concentrated high-titer lacZ-harboring retroviruses into experimental brain tumors RSV-M glioma cells (a murine anaplastic glioma cell line, derived from C3H/HeN mice) 13 were inoculated into the brains of C3H/HeN mice and 3 l of lacZ-harboring concentrated virus were inoculated into the tumor mass 20 days later. Mice were killed 5 days after the injection of viruses and slices of their brains were stained with Xgal reaction mixture. Thick blue staining was observed in approximately one quarter of the area of the large tumor mass after a single inoculation of only 3 l of viral supernatant ( Figure 1 ). This result revealed the extremely high transduction efficiency of concentrated high-titer retroviruses.
Effect of GCV-administration periods on antitumor activity against subcutaneous tumors inoculated with HTK-harboring retrovirus Subcutaneous RSV-M tumors with diameters of 10 mm were inoculated with HTK-harboring viral supernatant followed by intraperitoneal administration of GCV by three different protocols. The first group received GCV daily from day 2 to day 4; the second group received GCV from day 4 to day 6, and the third group received GCV from day 2 to day 6. The diameter of the subcutaneous tumor was measured for 20 days. Preliminary results indicated that the third protocol most effectively suppressed tumor growth (data not shown). The diameter of the tumor decreased to 6 mm on day 8. However, tumor size increased to 6.5 mm on day 10, 4 days after the last GCV administration, indicating regrowth of the tumor. Since regrowth is necessary for the retrovirus to infect the tumor effectively, we decided to treat tumor-bearing animals with GCV 2 to 6 days after retrovirus injection, followed by another retroviral injection after a 4 day interval ( Figure 2 ).
Efficient growth suppression of experimental murine brain tumors by repetitive therapy including inoculation of concentrated HTK-harboring retroviruses and GCV administration Mice were implanted with RSV-M glioma cells and treated with concentrated HTK-harboring retroviruses on day 3. They were intraperitoneally administered with GCV from day 5 to day 9 (2 to 6 days after viral inoculation). The second and third therapies, including viral inoculation and GCV administration, were initiated 4 days after the previous therapy; thus there is a 4-day period between the end of one cycle and the beginning of the next cycle of treatment. Brain slices from control mice (control A received lacZ-harboring virus instead of HTK-harboring virus and control B did not receive GCV administration) exhibited big tumor masses after the third therapy (Figure 3a ). On the other hand, slices from treated mice contained small tumors (Figure 3b ) or exhibited just the tract or scar of the injection needle ( Figure  3c ). Tumor volumes from these mice were measured and plotted ( Figure 4) . The difference between the treated group and control groups was moderate following the second therapy. However, the therapeutic effects became significantly different (P Ͻ 0.005) on day 30 after the third therapy.
Survival curves of treated and control mice
Mice harboring the RSV glioma were inoculated three times with high-titer HTK-harboring retroviruses, concentrated lacZ-harboring retroviruses (control I), or unconcentrated HTK-harboring retroviruses (titer: 3 × 10 c.f.u./ml) (control II) followed by GCV administration. Their survival was recorded as shown in Figure 5 . The median survival time was 23 days and all mice were dead within 38 days in either control group. In contrast, only one mouse died within 53 days when treated with the concentrated HTK-harboring virus. The cause of death was attributed to the presence of huge intracranial tumors.
Discussion
The preferential infection and integration of replicationdeficient retroviral vectors into the genome of actively dividing cells facilitates their utilization in the transduction of the HTK gene into brain tumors in clinical trials of gene therapy in the treatment of malignant brain tumors. [14] [15] [16] Recent clinical studies at the National Institutes of Health have revealed that a clinical protocol adopting retroviral vectors and the HTK/GCV system was effective against small tumors with few side-effects. 16 Yet, the ineffective nature of this protocol against large tumors necessitates the development of techniques to improve virus distribution and gene delivery. In the present study we developed high-titer retroviruses and demonstrated its effectiveness in the treatment of gliomas.
A unique property of the HTK/GCV system has been discovered while treating brain tumors. 17 Tumor cells that did not express the HTK suicide gene were also eliminated together with the HTK-bearing cells. Hence, this effect has been designated the bystander effect because HTK-positive cells can induce the death of HTK-negative neighboring (or bystander) cells. Through the bystander effect, effective tumor ablation is achieved, if merely 10-20% of the tumor cells contain the HTK gene. While the exact mechanism of this effect remains to be elucidated, the transport of phosphorylated GCV through gap junctions among tumor cells and the immune response caused by dead tumor cells are suggested to play important roles. 18, 19 This provides a distinct advantage when treating solid tumors, as the transduction of suicide genes to the entire tumor may be extremely difficult. Until now, the major limitation of retrovirus-mediated gene transfer has been its low transduction efficiency. One of the most promising strategies to overcome this restriction is through the inoculation of virus-producing cells within the tumor, in the hope that these cells should continue viral production and transduce HTK genes to surrounding tumor cells for several days until they are rejected or dead. As recent clinical trials demonstrate, this strategy proved successful to some extent against small tumors, but single implantation into large tumors failed to eliminate tumors. 16 This suggests the necessity of multiple implantations of virus-producing cells within tumors. On the other hand, however, repeated transplantation of murine virus-producing fibroblast cells into the human brain poses the danger of an increase in severe side-effects. Repeated xenoplantation into the brain may cause graft-versus-host (GVH) reactions due to the destruction of the blood-brain barrier. A more feasible alternative would be repeated inoculation of the virus itself.
We initially developed new virus-producing cells to obtain a high-titer virus supernatant through the introduction of the polyoma early gene. 8 Activation of the LTR (long terminal repeat) promoter by the polyoma early gene products increased the titer of the cell culture medium to 10 7 to 10 8 (c.f.u./ml) before concentration. Since the increased titer of the retrovirus preparation was associated with an increased amount of viral genomic RNA (data not shown), we believe that the proportion of viral particles lacking genomic RNA is far lower in our viral preparation than in previous preparations. This may have resulted in quantitative recovery during the concentration procedure. Until now, the transduction of 10 to 20% of tumor tissue in patients by direct intratumoral inoculation of retroviruses has proved improbable. However, our improved retroviral preparations have enabled transgene transduction to greater than 10% of the tumor cells, hence facilitating elimination of the entire tumor through the bystander effect.
Previous attempts employing direct retroviral injection, a method limited by lower transduction efficiency, rather than injection of virus-producing cells, have proved unsuccessful. 20 The titer of our concentrated retrovirus supernatant ranges from at least 10 10 to 10 11 (c.f.u./ml) while the highest titer used thus far in either animal models or clinical trials was 10 7 (c.f.u./ml). Hence, we have succeeded in a 10 3 -to 10 4 -fold increase in retroviral titer. The improved retroviral titer produced a dramatic effect 
on day 30 (n = 5). Control B mice, which received HTKharboring virus but did not receive GCV administration, had tumors of 39.6 mm 3 in volume on day 20 (n = 5), and 145.3 mm 3 on day 30 on average (n = 5). On day 30, The difference in tumor volumes between the treated group and control groups was significant (P Ͻ 0.005).
on transduction efficiency in vivo, and the repetitive administration of high-titer retrovirus eradicated a subcutaneous tumor originating from a hepatocellular carcinoma. 12 Thus, the repetitive administration of concentrated high-titer retrovirus may surpass the implantation of virus-producing cells in antitumor efficacy. While retroviruses are believed to be relatively less cytotoxic and nonimmunogenic, the safety of concentrated hightiter virus remains to be tested in humans, though we have not observed any adverse effects in mice. These issues must await to be addressed in phase I clinical trials.
As discussed in our recent report, the application of the HTK/GCV system necessitates a well-considered and executed schedule of GCV administration. 9 HTK genetransduced glioma cells can divide, migrate and move toward the periphery of the tumor. It is therefore necessary to await sufficient proliferation and migration of these cells to obtain maximal efficacy through the bystander effect. Furthermore, following inoculation of HTK-harboring retroviruses, the estimation of tumor growth in the brain provides a difficult challenge because stereotactic inoculation into the small brains of mice is less accurate in comparison to inoculation into human brains. On the other hand, the inoculation of viruses into subcutaneous tumors is relatively easy and accurate. In this study, we preliminarily investigated the response of tumor cells to HTK/GCV treatment. Repetitive 4-day administration of GCV effectively reduced the tumor size in contrast to a 2-day administration protocol. Furthermore, starting GCV administration 2 days after viral inoculation was more effective than initiating GCV treatment 4 days after viral inoculation. Our experiments have also revealed that regrowth of the subcutaneous tumor occurs 4 days after GCV treatment (data of subcutaneous tumor model not shown). While the regrowth of tumors 
linear line represents the mice that received concentrated retrovirus harboring the HTK gene. A dashed line represents the mice which received concentrated retrovirus harboring the lacZ-gene (control I). A dotted line represents the mice that received unconcentrated retrovirus harboring the HTK gene (control II).
permits effective infection of the tumor cells by retroviruses, the prolonged wait for this event would obviate any potential benefits for the patient. We therefore decided to apply the protocol shown in Figure 2 .
Based on our results, clinical trials using the direct inoculation of concentrated high-titer retrovirus together with the HTK/GCV system, would obligate the inoculation of viruses in the periphery of the tumor at least three times followed by GCV administration. In addition, careful consideration of the interval not only between the inoculation of viruses and the start of GCV treatment, but also between the last GCV treatment and the next inoculation of viruses should be made. In human brains tumor regrowth can easily be assessed by magnetic resonance imaging, enabling the determination of GCV administration schedules according to the image. Our studies are highly promising for the improvement of all clinical trials adopting the HTK/GCV system in the treatment of human malignant glioma.
Kuriyama et al 12 reported the complete eradication of hepatocellular carcinoma in subcutaneous tissues of mice by repeated injections of retroviruses. However, the viral titer used in these studies was less than 10 8 c.f.u./ml, and thus the volume injected was 100 l. In contrast, our experiments only required 3 l of concentrated retroviruses for one injection. The direct intracranial inoculation of the reagent is limited by its volume because of the risk of increasing intracranial pressure. We have often observed that slight increases in intracranial pressure prove critical for brain tumor patients. This report, therefore, provides the first evidence for the promising applicability of repeated direct inoculations of concentrated retrovirus harboring the HTK gene followed by GCV treatment in the eradication of malignant gliomas in the brain.
Materials and methods
Plasmid construction All plasmids were constructed by standard recombinant DNA techniques. 21 In the past, we have used the Cell culture and production of cells yielding high-titer HTK-harboring virus RSV-M glioma cells were provided by Dr T Kumanishi.
PAMP51/SVpIP201
+ cells (producing amphotropic retrovirus harboring the lacZ gene), and PsiMP34/ MBPpIP250 + cells (producing ecotropic retrovirus harboring the HTK gene) were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO BRL, Rockville, MD, USA) containing 10% fetal bovine serum (FBS; ICN Biomedicals Japan, Osaka, Japan), 100 units of penicillin (Meiji Seika, Tokyo, Japan) per ml, and 100 g of streptomycin (Meiji) per ml. 9 PsiMP34 is a modified ecotropic retrovirus-packaging cell line derived from Psi-2 (kindly provided by Dr Mulligan), by the introduction of the polyomavirus early region. 8, 26 Cells grown on 6-cm Falcon 3001 dishes (Becton Dickinson, Oxnard, CA, USA) were transfected with plasmid MBP/pIP250
+ by using LipofectAMINE Reagent (GIBCO). Cells (1 × 10 5 ) were seeded on Falcon 3001 dishes 1 day before transfection. Plasmid MBP/pIP250 + (1 g) was mixed with 5 l of LipofectAMINE reagent in 200 l of serum-free DMEM. After 1 h at room temperature, 800 l of serum-free DMEM was added. The mixture was layered on to the cells. Four hours later, the medium was replaced with 2 ml of fresh DMEM containing 10% FBS. Two days later, the medium was exchanged with fresh medium containing G418 (GIBCO) at a concentration of 1.0 mg/ml.
22
G418-resistant stable transformants, PsiMP34/MBP/ pIP250 + , were obtained after selection with G418 and cloned by a series of limiting dilution techniques. 8 Titers of clones were estimated by counting G418-resistant colonies of NIH3T3 cells infected with the supernatant of each clone. 27 The highest-titered retrovirus-producing cell clone was selected and used for experiments.
Concentration of retroviruses
Virus-producing cells (1.3 × 10 6 ) were seeded in 50 ml of medium in a Falcon 3024 flask and incubated at 32°C for 5 days. Supernatants from 10 flasks (500 ml) were collected and centrifuged by the method described by Bowles et al. 28 The original titer of the supernatant was 1.0-3.0 × 10 7 c.f.u./ml. Supernatants were centrifuged at 6000 g for 16 h at 4°C in 250 ml disposable bottles. After centrifugation, the supernatant was removed and the pellet (usually not visible at this stage) was resuspended in 5 ml (1% of the starting volume) of medium and then filtered through a 0.45-m filter. Resuspension was performed by a pipet whose tip was cut and broadly opened to prevent sticking of the pellet to the pipet. Resuspended samples were then centrifuged at 6000 g for 16 h at 4°C in 1.5 ml Eppendorf tubes. The supernatant was removed by aspiration and the pellet was resuspended with Hank's balanced salt solution (HBSS) (0.01% of the starting volume). The final volume of media including viruses was 50 l. The virus titer was concentrated up to 1.4-2.5 × 10 11 c.f.u./ml. These samples were used directly for experiments.
Inoculation of glioma cells and lacZ-harboring or HTKharboring virus into murine brains Eight-week-old female C3H/HeN mice weighing 17-22 g were anesthetized by intraperitoneal administration of pentobarbital (Abbott Laboratories, North Chicago, IL, USA) (50 mg/kg of body weight) and placed in a stereotactic apparatus (David Kopf Instruments, Tujunga, CA, USA). RSV-M glioma cells were trypsinized, washed twice with phosphate buffered saline (PBS), and resuspended in PBS at a concentration of 1 × 10 5 cells/l. A head burr hole, 0.5 mm in diameter, was made 3 mm to the right and 1 mm anterior to the bregma with an electric drill after a mid-line skin incision. A glioma cell suspension, 1 × 10 5 cells in 1 l of PBS, was inoculated by using a 10-l Hamilton syringe with a 26-gauge needle connected to a stereotactic arm through the burr hole. The cell suspension was inoculated at a depth of 3 mm from the dura (corresponding to the lateral area of the right striatum) over a period of more than 2 min. The needle was left in place for 3 min and then withdrawn slowly over 1 min. The skin wound was closed with a silk suture. LacZ-harboring or HTK-harboring virus was inoculated in the same way.
X-gal reaction of brain slices after the implantation of concentrated lacZ-harboring viruses into the tumor mass formed in murine brains C3H/HeN mice were inoculated with 1 × 10 5 RSV-M glioma cells as described before. Twenty days later, mice were inoculated with 3 l of lacZ-harboring concentrated virus, PAMP51/SVpIP201
